PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 393 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ¿Qué deben saber las personas con cáncer sobre el consumo de... January 11, 2022 FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC June 19, 2020 Five Questions With…Sharon. May 12, 2022 Steroids May Limit the Effectiveness of Immunotherapy for Brain Cancer December 28, 2020 Load more HOT NEWS “That is what I dream”: India’s journey to rolling out the... Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent... How Writing Helped Me Cope During Cancer FDA Grants Accelerated Approval to Tafasitamab-cxix for DLBCL
